177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
用户P-mPQbgVJoNg
1个月前
73
10
已完结
1. 系统已在2026-04-09 13:27:01对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/S0140-6736(24)01653-2
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0140673624016532
其他信息:
出版社: Elsevier BV
作者: Michael J Morris; Daniel Castellano; Ken Herrmann; Johann S de Bono; Neal D Shore; Kim N Chi; Michael Crosby; Josep M Piulats; Aude Fléchon; Xiao X Wei; Hakim Mahammedi; Guilhem Roubaud; Hana Študentová; James Nagarajah; Begoña Mellado; Álvaro Montesa-Pino; Euloge Kpamegan; Samson Ghebremariam; Teri N Kreisl; Celine Wilke; Katja Lehnhoff; Oliver Sartor; Karim Fizazi
